Evidence map›Paper›PMID 39743618›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

[

Runjun Yang, Han Tang, Yunze Xie, Danjie Cai, Yibo He, Zhe Zheng, Yu Lin, Huaping Gao, Wenxin Tang, Yihan Yan and 2 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04215471 (The Safety and Feasibility of NeoAdjuvant Therapy With Immunoreagent), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04215471 phase2unknown statusnot on this map

The Safety and Feasibility of NeoAdjuvant Therapy With Immunoreagent (PD-L1 Antibody SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma (NATION1907II)

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2020 to 2022Enrolled30ConditionsOesophageal Squamous Cell CarcinomaArmsPD-L1 Antibody SHR-1316
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Runjun Yang *Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
Han Tang *Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yunze XieDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
Danjie CaiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
Yibo HeDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
Zhe ZhengDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
Yu LinDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
Huaping GaoDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
Wenxin TangDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
Yihan YanDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
Lijie TanCancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Tan.lijie@zs-hospital.sh.cn.
Hongcheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China. shi.hongcheng@zs-hospital.sh.cn.ORCID 0000-0001-7457-876X

Funding

Chinese National Key Clinical Specialty Program YWP2022-007Innovative Medical Device Application Demonstration Program of Shanghai Municipal Commission of Economy and Informatization 23SHS01200National Key Research and Development Program of China 2022YFC2406902
6 · The paper itself

Abstract

purposeTo investigate the predictive value of 2-[18F]-fluoro-2-deoxy-D-glucose ([

methodsIn the single-arm phase 1b NATION-1907 trial (NCT04215471), 23 patients with LA-ESCC received two cycles of neoadjuvant PD-L1 blockade Adebrelimab followed by surgery. Among these, 18 patients underwent [

resultsIn the PT analysis, 10 patients were classified as PT well-responders and 8 as PT poor-responders. All post-treatment metabolic parameters, except MTV, were significantly lower in well-responders compared to poor-responders. The %ΔMTV, %ΔTLG were significantly higher in the poor-responder group (all P < 0.05). ROC curves indicated %ΔMTV

conclusionThe metabolic parameters of [

Indexed as

B7-H1 AntigenEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFluorodeoxyglucose F18Neoadjuvant TherapyPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMaleMiddle AgedTreatment OutcomeB7-H1 AntigenFluorodeoxyglucose F18[18F]FDG PET/CTLocally advanced esophageal squamous cell carcinomaPathological responsePD-L1 blockade monotherapy

Identifiers

PMID39743618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.